Rasul Kakil I, Mohammaed Kelta, Abdalla Awidi S, Chong-Lopez Augustin, Ahmad Mubarak A, Al-Homsi Mohammed U, Al-Hassan Asma M, Al-Alosi Ahmad S, Bener Abdulbari
Department of Medicine Hematology/Oncology Section, PO Box 3050, Doha, Qatar.
Saudi Med J. 2003 Aug;24(8):832-6.
The study is aimed at determining the prevalence of HER2/neu overexpression in Qatari women with breast cancer and to assess the survival in patients with HER2/neu positive tumors.
This is a retrospective study of clinical data of 70 Qatari female patients diagnosed with breast cancer during the period 1991 through to 2001, at Hamad Medical Corporation, Doha, Qatar. We also performed a retrospective review of breast tissue sample for those patients using paraffin sections and applying immunohistochemistry staining-[Hercep test (DAKO Inc)] to determine the HER2/neu status.
Eighteen patients (26%) were HER2/neu positive (2+ and 3+) with a mean age at diagnosis of 49.3years, and 52 (74%) were negative (0 and 1+) with mean age at diagnosis of 46.6 years. Of the patients with positive HER2/neu, 5 (28%) had a relapse of the disease and 4 (22%) died of the disease during follow up. Of the patients with HER2/neu, negative test 9 (17%) had a relapse of the disease and 10 (19%) died of the disease. The median survival function at mean of covariates for HER2/neu positive patients was 26 months, and for HER2/NEU negative patients was 28 months.
The prevalence of HER2/neu over expression in Qatari female with breast cancer in this study is 26%, but due to a small sample size it may not reflect really the prevalence. Patient with HER2/neu positive were older at diagnosis than patients with HER2/neu negative, also they had higher relapse rate and mortality. Median survival function was better for HER2/neu negative patients.
本研究旨在确定卡塔尔乳腺癌女性患者中HER2/neu过表达的患病率，并评估HER2/neu阳性肿瘤患者的生存率。
这是一项对1991年至2001年期间在卡塔尔多哈哈马德医疗公司诊断为乳腺癌的70名卡塔尔女性患者临床数据的回顾性研究。我们还对这些患者的乳腺组织样本进行了回顾性分析，使用石蜡切片并应用免疫组织化学染色法（Hercep检测，达科公司）来确定HER2/neu状态。
18名患者（26%）为HER2/neu阳性（2+和3+），诊断时平均年龄为49.3岁，52名患者（74%）为阴性（0和1+），诊断时平均年龄为46.6岁。在HER2/neu阳性患者中，5名（28%）疾病复发，4名（22%）在随访期间死于该疾病。在HER2/neu检测阴性的患者中，9名（17%）疾病复发，10名（19%）死于该疾病。HER2/neu阳性患者在协变量均值下的中位生存函数为26个月，HER2/NEU阴性患者为28个月。
本研究中卡塔尔乳腺癌女性患者HER2/neu过表达的患病率为26%，但由于样本量较小，可能无法真实反映患病率。HER2/neu阳性患者诊断时年龄比HER2/neu阴性患者大，且复发率和死亡率更高。HER2/neu阴性患者的中位生存函数更好。
